Tag: antipsychotic
The 30th Anniversary of PANSS Special Edition
[See sliding content bar above or scroll to bottom of page for complete list of articles included in this special edition of ICNS] Dear Colleagues: Thirty years ago, the Positive and Negative Syndrome Scale (PANSS) was developed and published by Stanley Kay, Abraham Fiszbein, and Lewis Opler to identify the presence and severity of psychopathology […]
Sensitivity of the Positive and Negative Syndrome Scale (PANSS) in Detecting Treatment Effects via Network Analysis
by Farnaz Zamani Esfahlani, MS; Hiroki Sayama, DSc; Katherine Frost Visser, MS; and Gregory P. Strauss, PhD Ms. Zamani Esfahlani is a PhD candidate in the Systems Science program at the State University of New York at Binghamton. Dr. Sayama is the director of the Center for Collective Dynamics of Complex Systems (CoCo), professor in […]
Severe Hypoglycemia Associated With Tiapride In An Elderly Patient With diabetes and Psychosis
Innov Clin Neuro. 2017;14(1–2):12–13
Cariprazine for Schizophrenia and Bipolar Disorder
by Jonathan R. Scarff, MD Dr. Scarff is a staff psychiatrist at the Veterans Affairs Outpatient Clinic in Spartanburg, South Carolina, USA Innov Clin Neurosci. 2016;13(9–10):49–52 Funding: The author has received no financial support for the writing of this manuscript. Financial Disclosures: The authors has no financial dislosures relevant to the content of this article. […]
Brexpiprazole: A New Treatment Option for Schizophrenia
by Jonathan R. Scarff, MD Dr. Scarff is with Veterans Affairs Outpatient Clinic, Spartanburg, South Carolina. Innov Clin Neurosci. 2016;13(7–8):26–29 Funding: No funding was received for the preparation of this manuscript. Financial disclosures: The author has no financial disclosures relevant to the content of this article. Key words: Schizophrenia, brexpiprazole, antipsychotic Abstract: Schizophrenia occurs in […]
Letter to the Editor: Comparing Injection Site Pain with Paliperidone Palmitate Versus First-generation Depot Antipsychotics in Subjects with Schizophrenia
Dear Editor: Atypical long-acting injectable (LAI) antipsychotics may improve treatment options for patients with serious mental illnesses, such as schizophrenia and bipolar disorder.[1] A systematic review of 1,700 outpatients from 10 different studies reported a 30-percent decrease in the relative risk for relapse with LAIs versus oral antipsychotic medications.[2] However, first-generation depot medications, such as […]
Lurasidone: A New Treatment Option for Bipolar Depression— A Review
by Radhika Bawa, MD, and Jonathan R. Scarff, MD Dr. Bawa is with Lehman College, the City University of New York, Bronx, New York; and Dr. Scarff is with Veterans Affairs Outpatient Clinic, Spartanburg, South Carolina. Innov Clin Neurosci. 2015;12(1–2):21–23
Rationale for Iloperidone in the Treatment of Posttraumatic Stress Disorder
by Michael D. Shuman, PharmD, and Ian R. McGrane, PharmD Dr. Shuman is Assistant Professor, Pharmacy Practice, Rosalind Franklin University of Medicine and Science College of Pharmacy, North Chicago, Illinois, and Pharmacy Specialist, Mental Health, Captain James A. Lovell Federal Health Care Center, North Chicago, Illinois; Dr. McGrane is a Clinical Pharmacist, St. Joseph Medical […]
Comparison of the Peak-to-trough Fluctuation in Plasma Concentration of Long-acting Injectable Antipsychotics and Their Oral Equivalents
by John J. Sheehan, PhD; Kristin R. Reilly, PharmD; Dong-Jing Fu, MD, PhD; and Larry Alphs, MD, PhD Dr. Sheehan was an employee of Janssen Scientific Affairs, LLC, Titusville, New Jersey, at the time of this analysis and is currently an employee of Bristol-Myers Squibb, Plainsboro, New Jersey; Drs. Reilly, Fu, and Alphs are employees […]
Trends in Combination Antipsychotic Use Among Persons With Commercial Insurance: A Data Snapshot
by Leslie Citrome, MD, MPH; Zhenchao Guo, PhD; Iftekhar Kalsekar, PhD; Robert A. Forbes, PhD; and Tony Hebden, PhD Dr. Citrome is with the Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York; Drs. Kalsekar, Guo, and Hebden are with Bristol-Myers Squibb, Plainsboro, New Jersey Dr. Forbes is with Otsuka Pharmaceutical […]
